Oncolytics Biotech Stock Price and Value Analysis

Oncolytics Biotech (NasdaqCM:ONCY) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Oncolytics Biotech to reach your target.

Target type
AdvantagesDisadvantagesNeutral
  • This stock looks overpriced.
  • This company is less known than others.
  • This company is not making money.
  • This company pays no dividend.

Inside the ONCY Numbers

ONCY Price
(Oncolytics Biotech stock price per share)
$0.39
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Drug Manufacturers - General stocks
[?] Cash Yield -25.02%
[?] Free Cash Flow Jitter 29%

Insider Activity Summary

No open-market insider buys or sells are recorded in the six months to 2026-11-20.

The six months before that had 14 buys and 0 sales.

Recent Insider Activity

Open-market buys and sells reported by Oncolytics Biotech's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-03-12 Kelly Jared (Chief Executive Officer) Buy 5,050 $0.96
2026-03-11 Parsons James T. Buy 10,000 $1.03
2026-02-12 Look Kirk (Chief Financial Officer) Buy 12,000 $0.84
2026-02-12 Pisano Wayne Buy 30,000 $0.84
2026-02-12 Heineman Thomas Charles (Chief Medical Officer) Buy 12,132 $0.83
2026-02-12 Brown Deborah Margaret Buy 25,000 $0.85
2026-02-12 Kelly Jared (Chief Executive Officer) Buy 29,500 $0.84
2026-02-12 Hagerman Allison (VP, Product Development) Buy 10,000 $0.83
2026-02-12 Seizinger Bernd R. Buy 40,000 $0.85
2026-02-12 Andrews Patricia S Buy 35,400 $0.86

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 8,679,124 shares shorted. With 125,536,642 shares available for purchase and an average trading volume over the past 10 trading days of 1,372,330, it would take at least 6.3 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Price Versus Our Estimated Value

Free cash flow was negative in every one of the 2 fiscal years we have for Oncolytics Biotech under its current filer.

Free cash flow is uneven from year to year, with a variability measure of 29%.

We do not estimate a fair value for Oncolytics Biotech while its free cash flow growth is not positive, so there is no value comparison here.

Dividends are not in our data for Oncolytics Biotech.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Oncolytics Biotech, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Oncolytics Biotech (ONCY) 53.2 - - - -
LifeVantage Corporation (LFVN) 62 23.3 4.0% - 85% above
SIGA Technologies (SIGA) 190 265.0 - 7.1% 86% below
Collegium Pharmaceutical (COLL) 783 23.1 - - 160% above
Amphastar Pharmaceuticals (AMPH) 1,199 12.9 - 0.8% 97% above
Innoviva (INVA) 1,309 7.8 - - 12% above
Phibro Animal Health Corporation (PAHC) 1,384 13.6 1.3% - 87% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1129928.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Only 2 years of cash-flow data from the current SEC filer are available. Averages and trends rest on a short record.
  • Free cash flow was negative in 2 of the 2 years we have.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-19
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ONCY annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ONCY

Does Oncolytics Biotech have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ONCY

This example shows how we apply the Trendshare checklist to ONCY: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 0.39
    • Market cap: $53M
    • EPS: -0.33
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: -28.2%
    • Date checked: Nov 19, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.